H
Howard R. Terebelo
Researcher at Providence Hospital
Publications - 74
Citations - 1513
Howard R. Terebelo is an academic researcher from Providence Hospital. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 14, co-authored 61 publications receiving 1334 citations. Previous affiliations of Howard R. Terebelo include St. John Providence Health System.
Papers
More filters
Journal ArticleDOI
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
David J. Kuter,James B. Bussel,Roger M. Lyons,Vinod Pullarkat,Terry Gernsheimer,Francis M. Senecal,Louis M. Aledort,James N. George,Craig M. Kessler,Miguel A. Sanz,Howard A. Liebman,Frank T. Slovick,J. Th. M. de Wolf,Emmanuelle Bourgeois,Troy H. Guthrie,Adrian C. Newland,Jeffrey S. Wasser,Solomon I. Hamburg,Carlos Grande,François Lefrère,Alan E. Lichtin,Michael D. Tarantino,Howard R. Terebelo,Jean François Viallard,Francis J. Cuevas,Ronald S. Go,David H. Henry,Robert L. Redner,Lawrence Rice,Martin R. Schipperus,D. Matthew Guo,Janet L. Nichol +31 more
TL;DR: Romiplostim was well tolerated, and increased and maintained platelet counts in splenectomised and non-splenECTomised patients with ITP and treatment safety was good.
Journal ArticleDOI
CD28-mediated regulation of multiple myeloma cell proliferation and survival
Nizar J. Bahlis,Anne M. King,Despina Kolonias,Louise M. Carlson,Hong Yu Liu,Mohamad A. Hussein,Howard R. Terebelo,Gerald E. Byrne,Bruce L. Levine,Lawrence H. Boise,Kelvin P. Lee +10 more
TL;DR: It is found that direct activation of myeloma cell CD28 by anti-CD28 mAb alone induces activation of PI3K and NFkappaB, suppresses MM cell proliferation, and protects against serum starvation and dexamethasone (dex)-induced cell death.
Journal ArticleDOI
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Moshe Talpaz,Ronald Paquette,Lawrence B. Afrin,Solomon I. Hamburg,Josef T. Prchal,Katarzyna Jamieson,Howard R. Terebelo,Gregory L. Ortega,Roger M. Lyons,Ramon V. Tiu,Elliott F. Winton,Kavita Natrajan,Olatoyosi Odenike,David F. Claxton,Wei Peng,Peter O'Neill,Susan Erickson-Viitanen,Lance Leopold,Victor Sandor,Richard S. Levy,Hagop M. Kantarjian,Srdan Verstovsek +21 more
TL;DR: Results suggest that a low starting dose of ruxolitinib with escalation to 10 mg BID may be appropriate in myelofibrosis patients with low platelet counts.
Journal ArticleDOI
Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited.
TL;DR: It is too soon to declare a causal relationship at this time, but there appears to be an increased number of SPMs in reports from several studies using lenalidomide maintenance, and patients should be educated regarding this potential concern.